- Home
- ASO vs XENE Comparison
ASO vs XENE Comparison
Compare ASO & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASO
- XENE
- Stock Information
- Founded
- ASO 1938
- XENE 1996
- Country
- ASO United States
- XENE Canada
- Employees
- ASO N/A
- XENE N/A
- Industry
- ASO Recreational Games/Products/Toys
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- ASO Consumer Discretionary
- XENE Health Care
- Exchange
- ASO Nasdaq
- XENE Nasdaq
- Market Cap
- ASO 3.1B
- XENE 2.5B
- IPO Year
- ASO 2020
- XENE 2014
- Fundamental
- Price
- ASO $37.85
- XENE $35.11
- Analyst Decision
- ASO Buy
- XENE Strong Buy
- Analyst Count
- ASO 17
- XENE 8
- Target Price
- ASO $59.18
- XENE $56.38
- AVG Volume (30 Days)
- ASO 2.3M
- XENE 870.9K
- Earning Date
- ASO 06-10-2025
- XENE 05-08-2025
- Dividend Yield
- ASO 1.38%
- XENE N/A
- EPS Growth
- ASO N/A
- XENE N/A
- EPS
- ASO 5.73
- XENE N/A
- Revenue
- ASO $5,933,450,000.00
- XENE N/A
- Revenue This Year
- ASO $4.93
- XENE N/A
- Revenue Next Year
- ASO $7.21
- XENE $1,553.36
- P/E Ratio
- ASO $6.61
- XENE N/A
- Revenue Growth
- ASO N/A
- XENE N/A
- 52 Week Low
- ASO $33.34
- XENE $26.74
- 52 Week High
- ASO $64.62
- XENE $46.00
- Technical
- Relative Strength Index (RSI)
- ASO 39.37
- XENE 55.88
- Support Level
- ASO $36.14
- XENE $32.35
- Resistance Level
- ASO $38.00
- XENE $34.08
- Average True Range (ATR)
- ASO 3.11
- XENE 2.43
- MACD
- ASO -0.21
- XENE 0.57
- Stochastic Oscillator
- ASO 30.98
- XENE 96.54
About ASO Academy Sports and Outdoors Inc.
Academy Sports and Outdoors Inc is engaged in the full-line sporting goods and outdoor recreation retailer in the United States. The company's product categories are outdoors, apparel, sports & recreation, and footwear.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.